Axogen, Inc. (AXGN) Form 10-Q — Oct 28, 2026
Axogen reported Q3 2026 revenue of $75.8 million, up 26.2% year-over-year, with quarterly net income of $2.3 million ($0.04 EPS). Nine-month revenue reached $207.0 million, up 25.2%, though the nine-month net loss widened to $18.8 million, driven by a $16.8 million loss on extinguishing the Oberland Credit Facility. The company now holds $348.1 million in cash and investments with zero long-term debt after raising $358.3 million net across January and September 2026 equity offerings at $31.00 and $42.50 per share, respectively. The September offering funded the $200 million all-cash acquisition of BioCircuit Technologies, completed October 1, 2026.
Key figures
- Eps
- 0.04
- Revenue
- 75834000
- Net Income
- 2334000
- Total Debt
- 0
- Revenue Yoy
- 26.2% (Q3)
- Total Assets
- 550339000
- Cash Position
- 328888000
- Shares Outstanding
- 59724524
- Gross margin q3
- 74.8%
- Trace investment
- 7000000
- Nine month revenue
- 207022000
- Trace ownership pct
- 18.9%
- Cash and investments
- 348068000
- Credit facility payoff
- 69707000
- September offering price
- 42.5
- Biocircuit purchase price
- 200000000
- Nine month revenue growth
- 25.2%
- September offering shares
- 5646500
- Loss on debt extinguishment
- 16849000
- January offering net proceeds
- 133252000
- Operating cash flow nine month
- 25322000
- September offering net proceeds
- 225029000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.